Partners in ALS ONE Join Forces to Advance Therapies for ALS

The ALS ONE partnership, founded in January 2016 by the late ALS patient Kevin Gosnell (see Jan 2016 news), has received a $2M funding commitment from the ALS Association to support ALS ONE initiatives. The Massachusetts-based partnership was founded to bring together leaders in the field of ALS from Massachusetts General Hospital, the ALS Therapy Development Institute (ALS TDI), University of Massachusetts Medical School and Compassionate Care ALS (CCALS), in order to accelerate ALS therapy development and improve patient care. The partner organizations are collaborating and coordinating their efforts across a variety of research and clinical programs, including improving accessibility of multidisciplinary ALS clinical care, establishing a clinical network for trials, developing new biomarkers and technologies, and testing gene therapies targeting the C9ORF72 expansions associated with ALS/FTD.

 

Click here to read the press release.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail

disease-als topic-clinical
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail